Rasagiline for the treatment of Parkinson’s disease: an update

@article{Stocchi2015RasagilineFT,
  title={Rasagiline for the treatment of Parkinson’s disease: an update},
  author={Fabrizio Stocchi and Chiara Fossati and Margherita Torti},
  journal={Expert Opinion on Pharmacotherapy},
  year={2015},
  volume={16},
  pages={2231 - 2241}
}
Introduction: Rasagiline is a potent, selective, irreversible Monoamine Oxidase-B (MAO-B) inhibitor, developed to prolong the action of dopamine in the brain. It has been demonstrated that rasagiline can improve motor and some non-motor symptoms (NMS) in both early and advanced Parkinson’s disease (PD) patients, and it also exhibits neuroprotective and antiapoptotic properties. Areas covered: The objective of this review, performed by a Medline search on the most recent papers investigating the… 
Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future.
TLDR
The effects of MAO-B inhibitors on motor and non-motor symptoms in PD patients, their mechanism of action, and the future development of MAo-B inhibitor therapy are discussed.
Switch from rasagiline to safinamide in fluctuating Parkinson’s disease patients: a retrospective, pilot study
TLDR
It is suggested that safinamide 100 mg may produce more powerful benefit that rasagiline 1 mg as add-on to levodopa in fluctuating PD patients, possibly because of the bimodal mechanism of action of the former drug.
Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson’s Disease: From Bench to Bedside
TLDR
Among all antiparkinsonian agents, MAOB inhibitors are those with the greatest neuropro-tective potential because of inhibition of dopamine metabolism, induction of neurotrophic factors, and, in the case of safina-mide, inhibition of glutamate release.
Adjunct rasagiline to treat Parkinson’s disease with motor fluctuations: a randomized, double-blind study in China
TLDR
In levodopa-treated Chinese patients with Parkinson’s disease and motor fluctuations, adjunct rasagiline 1 mg/day statistically significantly reduced OFF time, and improved daily function and overall well-being, versus placebo.
Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson’s disease: a systematic review
TLDR
R + l combination therapy was superior to l monotherapy for improvement of UPDRS scores and off-time in PD patients and was similar in terms of safety and tolerability.
Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease
TLDR
This study provides Class I evidence that for patients with early PD, preladenant is not effective as monotherapy at the doses studied (2, 5, 10 mg) and the lack of efficacy of the active control rasagiline makes it difficult to interpret the results.
Methylene blue and its analogues as antidepressant compounds
Methylene Blue (MB) is considered to have diverse medical applications and is a well-described treatment for methemoglobinemias and ifosfamide-induced encephalopathy. In recent years the focus has
A new MAP-Rasagiline conjugate reduces α-synuclein inclusion formation in a cell model.
TLDR
It is reported for the first time that conjugation of a current drug used in the therapy of PD with CPP reduces α-syn aggregation, which might prove beneficial in PD and other synucleinopathies.
Pharmacokinetics, Pharmacodynamics, and Safety of Rasagiline Transdermal Patch: A Preliminary Study in Healthy Chinese Subjects
TLDR
The prolonged t1/2, increased AUC0–t, and more stable plasma drug concentration of the rasagiline patch may permit a longer dosing interval compared to the oral tablet and was safe and well tolerated in healthy Chinese subjects.
Rasagiline derivatives combined with histamine H3 receptor properties.
The irreversible monoamine oxidase B (MAO B) inhibitor rasagiline has been described with multiple disease modifying effects in vitro on models of Parkinson's disease. The combination of this
...
1
2
3
...

References

SHOWING 1-10 OF 65 REFERENCES
Safety of rasagiline for the treatment of Parkinson's disease
TLDR
Rasagiline is effective and well tolerated in PD as monotherapy or in combination with levodopa, and the risk of serotonin toxicity with serotoninergic antidepressants remains insufficiently characterized, while current available data in small groups of subjects suggest a low risk.
Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease
  • F. Stocchi
  • Medicine
    International journal of clinical practice
  • 2006
TLDR
Rasagiline is a novel, second‐generation, irreversible, selective monoamine oxidase type B inhibitor that is indicated for the treatment of idiopathic PD, either as initial monotherapy or as adjunct therapy (with levodopa) for patients experiencing end‐of‐dose motor fluctuations.
Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
TLDR
A role for dopamine-enhancing therapies in NMSs in early PD is suggested and the combination of rasagiline and antidepressants in patients with de novo PD is associated with reduced worsening of a range of N MSs in preliminary analyses.
Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease
TLDR
Rasagiline is a well-tolerated MAO-B inhibitor that may help to achieve the desired level of clinical benefit in Parkinson's disease.
Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
TLDR
Evidence supporting a role for rasagiline as a neuroprotective molecule in the treatment of Parkinson's disease is presented.
A critical review of evidence for preclinical differences between rasagiline and selegiline
TLDR
Rasagiline is superior to selegiline in its potency to prevent spontaneous cell death seen in cell culture, and to reduce accelerated cell death following serum deprivation in vitro, and is more effective in regard to its ability to reverse changes in mitochondrial function that lead to apoptosis.
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial
TLDR
Once-daily rasagiline reduces mean daily off-time and improves symptoms of Parkinson's disease in levodopa-treated patients with motor fluctuations, an effect similar to that of entacapone.
Randomized, controlled trial of rasagiline as an add‐on to dopamine agonists in Parkinson's disease
TLDR
Rasagiline 1 mg/d provided statistically significant improvement when added to dopamine agonist therapy and was well tolerated, and the most common adverse events were dizziness and headache.
A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.
TLDR
Rasagiline is effective as monotherapy for patients with early PD and the 2 dosages in this trial were both effective relative to placebo.
Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial.
TLDR
It is demonstrated that rasagiline mesylate is effective and well tolerated as an adjunct to levodopa treatment in Chinese PD patients with fluctuations.
...
1
2
3
4
5
...